Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside

Respiratory Medicine

Volumn 109, Issue 10, 2015, Pages 1305-1311

  Cazzola, Mario ^a,b   Calzetta, Luigino ^a   Ora, Josuel ^b   Puxeddu, Ermanno ^a,b   Rogliani, Paola ^a,b   Matera, Maria Gabriella ^c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Aclidinium; COPD; Dual bronchodilation; Formoterol; Translation research

Indexed keywords

ACLIDINIUM BROMIDE; FORMOTEROL; SALBUTAMOL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; FORMOTEROL FUMARATE; MUSCARINIC RECEPTOR BLOCKING AGENT; TROPANE DERIVATIVE;

AGED; ARTICLE; BRONCHODILATATION; BRONCHUS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG POTENTIATION; EC50; EX VIVO STUDY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN TISSUE; IN VIVO STUDY; LOBECTOMY; LUNG CANCER; MALE; MAXIMUM DRUG EFFECT; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DOSE RESPONSE; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; LUNG; MIDDLE AGED; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TRANSLATIONAL RESEARCH;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; BRONCHI; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; FORMOTEROL FUMARATE; HUMANS; LUNG; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SINGLE-BLIND METHOD; TRANSLATIONAL MEDICAL RESEARCH; TROPANES;

EID: 84942885527     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2015.08.005     Document Type: Article

References (27)

1. M.G. Matera, P. Rogliani, B. Rinaldi, and M. Cazzola Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease Expert Rev. Clin. Pharmacol. 8 2015 35 41
2. G. Pelaia, R. Maselli, and M.G. Matera Treatment of chronic obstructive pulmonary disease by dual bronchodilation with coformulation of indacaterol/glycopyrronium Pharmacology 94 2014 249 258
3. M. Cazzola, and M. Molimard The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD Pulm. Pharmacol. Ther. 23 2010 257 267
4. M. Cazzola, L. Calzetta, C.P. Page, P. Rogliani, F. Facciolo, A. Gavaldà, and M.G. Matera Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi Eur. J. Pharmacol. 745 2014 135 143
5. A.S. LaPrad, T.L. Szabo, B. Suki, and K.R. Lutchen Tidal stretches do not modulate responsiveness of intact airways in vitro J. Appl. Physiol. 2010 109 1985 295 304
6. W. Freas, J.L. Hart, D. Golightly, H. McClure, and S.M. Muldoon Contractile properties of isolated vascular smooth muscle after photoradiation Am. J. Physiol. 256 1989 H655 H664
7. K. Hatake, and I. Wakabayashi Ethanol suppresses L-arginine-induced relaxation response of rat aorta stimulated with bacterial lipopolysaccharide Nihon Arukoru Yakubutsu Igakkai Zasshi 35 2000 61 68
8. E.R. Bleecker Cholinergic and neurogenic mechanisms in obstructive airways disease Am. J. Med. 81 1986 93 102
9. T.C. Chou Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol. Rev. 58 2006 621 681
10. L.S.G.A. Goodman, and L.L. Brunton Goodman & Gilman's Manual of Pharmacology and Therapeutics 2008 McGraw-Hill Medical New York
11. H. Motulsky, and A. Christopoulos Fitting Models to Biological Data Using Linear and Nonlinear Regression: a Practical Guide to Curve Fitting 2004 Oxford University Press Oxford
12. H. Motulsky Intuitive Biostatistics 1995 Oxford University Press New York; Oxford
13. B.R. Celli, and W. MacNee Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper Eur. Respir. J. 23 2004 932 946
14. GINA. Global Initiative for Asthma Guidelines: Global Strategy for Asthma Management and Prevention 2011 GINA In
15. W.R. Greco, G. Bravo, and J.C. Parsons The search for synergy: a critical review from a response surface perspective Pharmacol. Rev. 47 1995 331 385
16. M. Goldoni, and C. Johansson A mathematical approach to study combined effects of toxicants in vitro: evaluation of the Bliss independence criterion and the Loewe additivity model Toxicol Vitro 21 2007 759 769
17. P. Rogliani, L. Calzetta, E.A. Rendina, D. Massullo, M. Dauri, B. Rinaldi, A. Capuano, and M.G. Matera The influence of propofol, remifentanil and lidocaine on the tone of human bronchial smooth muscle Pulm. Pharmacol. Ther. 26 2013 325 331
18. M. Cazzola, L. Calzetta, A. Segreti, F. Facciolo, P. Rogliani, and M.G. Matera Translational study searching for synergy between glycopyrronium and indacaterol COPD 12 2015 175 181
19. L. Calzetta, C.P. Page, D. Spina, M. Cazzola, P. Rogliani, F. Facciolo, and M.G. Matera Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone J. Pharmacol. Exp. Ther. 346 2013 414 423
20. Y. Grabovsky, and R.J. Tallarida Isobolographic analysis for combinations of a full and partial agonist: curved isoboles J. Pharmacol. Exp. Ther. 310 2004 981 986
21. R.J. Tallarida An overview of drug combination analysis with isobolograms J. Pharmacol. Exp. Ther. 319 2006 1 7
22. R.J. Tallarida, and R.B. Raffa The application of drug dose equivalence in the quantitative analysis of receptor occupation and drug combinations Pharmacol. Ther. 127 2010 165 174
23. R.J. Tallarida Drug synergism: its detection and applications J. Pharmacol. Exp. Ther. 298 2001 865 872
24. L. Calzetta, M.G. Matera, and M. Cazzola Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy Eur. J. Pharmacol. 761 2015 168 173
25. D. Spina Pharmacology of novel treatments for COPD: are fixed dose combination LABA/LAMA synergistic? Eur. Clin. Respir. J. 2 2015 26634
26. L. Calzetta, M. Cazzola, C.P. Page, P. Rogliani, F. Facciolo, and M.G. Matera Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways Pulm. Pharmacol. Ther. 32 2015 15 23
27. J.F. Donohue, D. Singh, C. Munzu, S. Kilbride, and A. Church Evaluating lung function response to umeclidinium/vilanterol (UMEC/VI) 62.5/25mcg, UMEC 62.5 mcg and VI 25mcg in COPD patients Eur. Respir. J. 44 2014 P291